Skip to content
value.today

Cancer IQ Inc.

Total raised
$20 M
3 rounds on record
Latest round
$4 M
Nov 2023
First round on record
Feb 2020
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Cancer IQ Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2023$4 MNo. 3$2 to $10 million

Cancer IQ Inc.: Raise no. 3, Nov 2023

Investors in this round

9 investors had bought by the notice of May 26, 2026: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $6 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Haibo Olopade Lu · Executive Officer, Director
  • Olufeyikemi Olopade Ayodele · Executive Officer, Director
  • Carladenise Olopade Edwards · Director
  • Joel Olopade Krikston · Director
  • Mark Olopade Bakken · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Olufeyikemi Olopade Ayodele, Chief Executive Officer. Newest notice filed May 26, 2026 (1 amendment). Read the notice at the SEC.

debt, optionsSEC
Mar 2022$14 MNo. 2$10 to $50 million

Cancer IQ Inc.: Raise no. 2, Mar 2022

Investors in this round

6 investors had bought by the notice of Apr 8, 2022: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$396,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Haibo Olopade Lu · Executive Officer, Director
  • Olufeyikemi Olopade Ayodele · Executive Officer, Director
  • Andrea Olopade Metkus · Director
  • Joel Olopade Krikston · Director
  • Mark Olopade Bakken · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • B. C. Ziegler and Company (CRD 61) · Chicago, IllinoisSold in CA, IL, MA, NJ, NY, TX, WA, WI

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used to repay certain indebtedness of the Issuer and for product development and other general corporate purposes.”

Signed by Olufeyikemi Olopade Ayodele, President & CEO. Newest notice filed Apr 8, 2022. Read the notice at the SEC.

equitySEC
Feb 2020$2 MNo. 1Under $2 million

Cancer IQ Inc.: Raise no. 1, Feb 2020

Investors in this round

5 investors had bought by the notice of Apr 23, 2020: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher Olopade Bun · Executive Officer
  • Haibo Olopade Lu · Executive Officer
  • Olufeyikemi Olopade Ayodele · Executive Officer, Director
  • Paul Olopade Burton · Executive Officer
  • Evan Olopade Wood · Director
  • Jordan Olopade Dolin · Director
  • Mark Olopade Bakken · Director
  • Olufunmilayo Olopade Olapade · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Olufeyikemi Olopade Ayodele, Chief Executive Officer. Newest notice filed Apr 23, 2020. Read the notice at the SEC.

equity, debt, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cancer IQ Inc. chose not to state its revenue in its newest notice of a funding round (May 2026).

    SEC Form D · May 2026

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · May 2026

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Cancer IQ Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cancer IQ Inc.
NameRoleNamed in
Haibo Olopade LuExecutive officerMay 2026
Olufeyikemi Olopade AyodeleExecutive officerMay 2026
Christopher Olopade BunExecutive officerApr 2020
Paul Olopade BurtonExecutive officerApr 2020
Carladenise Olopade EdwardsDirectorMay 2026
Haibo Olopade LuDirectorMay 2026
Joel Olopade KrikstonDirectorMay 2026
Mark Olopade BakkenDirectorMay 2026
Olufeyikemi Olopade AyodeleDirectorMay 2026
Andrea Olopade MetkusDirectorApr 2022
Evan Olopade WoodDirectorApr 2020
Jordan Olopade DolinDirectorApr 2020
Olufunmilayo Olopade OlapadeDirectorApr 2020